Articles published in Molecular and Genetic Medicine have been cited by esteemed scholars and scientists all around the world.
Molecular and Genetic Medicine has got h-index 29, which means every article in Molecular and Genetic Medicine has got 29 average citations.
Following are the list of articles that have cited the articles published in Molecular and Genetic Medicine.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|---|---|
Total published articles |
40 | 53 | 61 | 59 | 33 | 62 | 69 |
Research, Review articles and Editorials |
1 | 8 | 7 | 12 | 21 | 38 | 42 |
Research communications, Review communications, Editorial communications, Case reports and Commentary |
39 | 45 | 54 | 47 | 12 | 24 | 27 |
Conference proceedings |
0 | 0 | 13 | 14 | 0 | 36 | 162 |
Citations received as per Google Scholar, other indexing platforms and portals |
4125 | 3135 | 348 | 369 | 376 | 335 | 318 |
Journal total citations count | 3919 |
Journal impact factor | 4.4 |
Journal 5 years impact factor | 6.21 |
Journal cite score | 6.74 |
Journal h-index | 29 |
Journal h-index since 2019 | 19 |
Ferrara F, Moles51 E, Böιcherâ€ÂFriebertshäuser E, Montomoli E, Cor54 D, Scoι S, Temperton N. The study of heterosubtypic an; body responses against Influenza A viruses elicited by seasonal vaccina; on using a pseudotype neutraliza; on assay. |
|
Ferrara F, Moles41 E, BöRcherâ€ÂFriebertshäuser E, Cor43 D, CaRoli G, ScoR S, Temperton N. Haemagglu4nin ac4va4on by human transmembrane protease serine 2 or human airway trypsinâ€Âlike protease is necessary for produc4on of high 4tre influenza A virus pseudotypes for the evalua4on of pandemic poten4al. |
|
Temperton NJ, Unit VP. Manuscript title. |
|
Mather S, Scott S, Temperton N, Wright E, King B, Daly J. Author Proof. |
|
Bentley E. The study of highly pathogenic emerging zoonotic virus envelope proteins through pseudotyped virus generation (Doctoral dissertation, University of Westminster). |
|
Temperton N. The Viral Pseudotype Unit: viral pseudotype R&D, dissemination and education. Future Virology. 2016 Feb;11(2):113-6. |
|
Ferrara F, Molesti E, Scott S, Cattoli G, Temperton N. The use of hyperimmune chicken reference sera is not appropriate for the validation of influenza pseudotype neutralization assays. Pathogens. 2017 Sep 25;6(4):45. |
|
Molesti E, Temperton N. Influenza serological assays: from agar to plasmid-based approaches. |
|
Wanner A. Alpha-1 Antitrypsin as a Therapeutic Agent for Conditions not Associated with Alpha-1 Antitrypsin Deficiency. InAlpha-1 Antitrypsin 2016 (pp. 141-155). Humana Press, Cham. |
|
Ferrara F, Moles E, Temperton N. Influenza, pseudotypes and pandemic preparedness. |
|
Wallerström S, Lagerqvist N, Temperton NJ, Cassmer M, Moreno A, Karlsson M, Leijon M, Lundkvist Å, Falk K. Full text document. |
|
Wallerström S. Serological and molecular methods for surveillance of influenza A virus. Inst för mikrobiologi, tumör-och cellbiologi/Dept of Microbiology, Tumor and Cell Biology; 2014 Nov 5. |
|
Scott SD, Kinsley R, Temperton N, Daly JM. The optimisation of pseudotyped viruses for the characterisation of immune responses to equine influenza virus. Pathogens. 2016 Dec 15;5(4):68. |
|
Li Q, Liu Q, Huang W, Li X, Wang Y. Current status on the development of pseudoviruses for enveloped viruses. Reviews in medical virology. 2018 Jan;28(1):e1963. |
|
Yamamoto M, Matsuyama S, Li X, Takeda M, Kawaguchi Y, Inoue JI, Matsuda Z. Identification of nafamostat as a potent inhibitor of Middle East respiratory syndrome (MERS) corona virus S-mediated membrane fusion using the split protein-based cell-cell fusion assay. Antimicrobial agents and chemotherapy. 2016 Aug 22:AAC-01043. |
|
King B, Temperton NJ, Grehan K, Scott SD, Wright E, Tarr AW, Daly JM. Technical considerations for the generation of novel pseudotyped viruses. Future Virology. 2016 Jan;11(1):47-59. |
|
Ferrara F, Molesti E, Temperton N. The application of pseudotypes to influenza pandemic preparedness. Future Virology. 2015 Jun;10(6):731-49. |
|
Mullin J, Ahmed MS, Sharma R, Upile N, Beer H, Achar P, Puksuriwong S, Ferrara F, Temperton N, McNamara P, Lambe T. Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by modified vaccinia Ankara-vectored influenza vaccines. Vaccine. 2016 Mar 29;34(14):1688-95. |
|
Temperton NJ, Wright E, Scott SD. Retroviral Pseudotypes–from scientific tools to clinical utility. eLS. 2001 May 30:1-1. |
|
Grehan K, Ferrara F, Temperton N. An optimised method for the production of MERS-CoV spike expressing viral pseudotypes. MethodsX. 2015 Jan 1;2:379-84. |
|
Molecular and Genetic Medicine received 3919 citations as per Google Scholar report